Trial Profile
A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Cotadutide (Primary) ; Liraglutide; Metformin
- Indications Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms REGENERATE
- Sponsors AstraZeneca
- 20 May 2021 Primary endpoint (Change in HbA1c) has been met as per results published in the Diabetes Care
- 20 May 2021 Primary endpoint (Percent Change in Body Weight) has been met as per results published in the Diabetes Care
- 20 May 2021 Results published in the Diabetes Care